专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07666583B2 Identification of cancer protein biomarkers using proteomic techniques 有权
标题翻译：使用蛋白质组学技术鉴定癌症蛋白质生物标志物
公开(公告)号：US07666583B2
公开(公告)日：2010-02-23
申请号：US11037889
申请日：2005-01-18
申请人： Gil G. Mor , David C. Ward , Patricia Bray-Ward
发明人： Gil G. Mor , David C. Ward , Patricia Bray-Ward
IPC分类号： C12Q1/00 , C40B30/00
CPC分类号： G01N33/57484 , C12Q1/6886 , C12Q2600/112 , C12Q2600/136 , C12Q2600/158 , G01N33/57415 , G01N33/57419 , G01N33/57449 , G01N2333/4703 , G01N2333/575 , G01N2333/5756 , G01N2333/65 , G01N2333/99 , G01N2500/04 , G01N2800/52 , G06F19/00
摘要： The claimed invention describes methods to diagnose or aid in the diagnosis of cancer. The claimed methods are based on the identification of biomarkers which are particularly well suited to discriminate between cancer subjects and healthy subjects. These biomarkers were identified using a unique and novel screening method described herein. The biomarkers identified herein can also be used in the prognosis and monitoring of cancer. The invention comprises the use of leptin, prolactin, OPN and IGF-II for diagnosing, prognosis and monitoring of ovarian cancer.
摘要翻译：所要求保护的发明描述了诊断或辅助诊断癌症的方法。所要求保护的方法基于特别适合于区分癌症受试者和健康受试者的生物标志物的鉴定。使用本文所述的独特和新颖的筛选方法鉴定这些生物标志物。本文鉴定的生物标志物也可用于癌症的预后和监测。本发明包括使用瘦蛋白，催乳素，OPN和IGF-II来诊断，预后和监测卵巢癌。

2. 发明申请

US20160018402A2 IDENTIFICATION OF CANCER PROTEIN BIOMARKERS USING PROTEOMIC TECHNIQUES 有权
公开(公告)号：US20160018402A2
公开(公告)日：2016-01-21
申请号：US14602916
申请日：2015-01-22
申请人： Gil G. Mor , David C. Ward , Patricia Bray-Ward
发明人： Gil G. Mor , David C. Ward , Patricia Bray-Ward
IPC分类号： G01N33/574
CPC分类号： G01N33/57484 , C12Q1/6886 , C12Q2600/112 , C12Q2600/136 , C12Q2600/158 , G01N33/57415 , G01N33/57419 , G01N33/57449 , G01N2333/4703 , G01N2333/575 , G01N2333/5756 , G01N2333/65 , G01N2333/99 , G01N2500/04 , G01N2800/52 , G06F19/00
摘要： The claimed invention describes methods to diagnose or aid in the diagnosis of cancer. The claimed methods are based on the identification of biomarkers which are particularly well suited to discriminate between cancer subjects and healthy subjects. These biomarkers were identified using a unique and novel screening method described herein. The biomarkers identified herein can also be used in the prognosis and monitoring of cancer. The invention comprises the use of leptin, prolactin, OPN and IGF-II for diagnosing, prognosis and monitoring of ovarian cancer.

3. 发明授权

US08975379B2 Identification of cancer protein biomarkers using proteomic techniques 有权
标题翻译：使用蛋白质组学技术鉴定癌症蛋白质生物标志物
公开(公告)号：US08975379B2
公开(公告)日：2015-03-10
申请号：US12644677
申请日：2009-12-22
申请人： Gil G. Mor , David C. Ward , Patricia Bray-Ward
发明人： Gil G. Mor , David C. Ward , Patricia Bray-Ward
IPC分类号： C07K16/00 , C12P21/08 , C40B40/10 , A61K39/395 , G01N33/574 , C12Q1/68
CPC分类号： G01N33/57484 , C12Q1/6886 , C12Q2600/112 , C12Q2600/136 , C12Q2600/158 , G01N33/57415 , G01N33/57419 , G01N33/57449 , G01N2333/4703 , G01N2333/575 , G01N2333/5756 , G01N2333/65 , G01N2333/99 , G01N2500/04 , G01N2800/52 , G06F19/00
摘要： The claimed invention describes methods to diagnose or aid in the diagnosis of cancer. The claimed methods are based on the identification of biomarkers which are particularly well suited to discriminate between cancer subjects and healthy subjects. These biomarkers were identified using a unique and novel screening method described herein. The biomarkers identified herein can also be used in the prognosis and monitoring of cancer. The invention comprises the use of leptin, prolactin, OPN and IGF-II for diagnosing, prognosis and monitoring of ovarian cancer.
摘要翻译：所要求保护的发明描述了诊断或辅助诊断癌症的方法。所要求保护的方法基于特别适合于区分癌症受试者和健康受试者的生物标志物的鉴定。使用本文所述的独特和新颖的筛选方法鉴定这些生物标志物。本文鉴定的生物标志物也可用于癌症的预后和监测。本发明包括使用瘦蛋白，催乳素，OPN和IGF-II来诊断，预后和监测卵巢癌。

4. 发明申请

US20100311047A1 Identification Of Cancer Protein Biomarkers Using Proteomic Techniques 有权
标题翻译：使用蛋白质组学技术鉴定癌症蛋白质生物标志物
公开(公告)号：US20100311047A1
公开(公告)日：2010-12-09
申请号：US12644677
申请日：2009-12-22
申请人： Gil G. Mor , David C. Ward , Patricia Bray-Ward
发明人： Gil G. Mor , David C. Ward , Patricia Bray-Ward
IPC分类号： C12Q1/68 , G01N33/53
CPC分类号： G01N33/57484 , C12Q1/6886 , C12Q2600/112 , C12Q2600/136 , C12Q2600/158 , G01N33/57415 , G01N33/57419 , G01N33/57449 , G01N2333/4703 , G01N2333/575 , G01N2333/5756 , G01N2333/65 , G01N2333/99 , G01N2500/04 , G01N2800/52 , G06F19/00
摘要： The claimed invention describes methods to diagnose or aid in the diagnosis of cancer. The claimed methods are based on the identification of biomarkers which are particularly well suited to discriminate between cancer subjects and healthy subjects. These biomarkers were identified using a unique and novel screening method described herein. The biomarkers identified herein can also be used in the prognosis and monitoring of cancer. The invention comprises the use of leptin, prolactin, OPN and IGF-II for diagnosing, prognosis and monitoring of ovarian cancer.
摘要翻译：所要求保护的发明描述了诊断或辅助诊断癌症的方法。所要求保护的方法基于特别适合于区分癌症受试者和健康受试者的生物标志物的鉴定。使用本文所述的独特和新颖的筛选方法鉴定这些生物标志物。本文鉴定的生物标志物也可用于癌症的预后和监测。本发明包括使用瘦蛋白，催乳素，OPN和IGF-II来诊断，预后和监测卵巢癌。

5. 发明授权

US07790463B2 Methods of determining whether a pregnant woman is at risk of developing preeclampsia 有权
标题翻译：确定孕妇是否处于发生先兆子痫的风险的方法
公开(公告)号：US07790463B2
公开(公告)日：2010-09-07
申请号：US11346694
申请日：2006-02-02
申请人： Gil G. Mor , Donna Neale , Roberto Romero
发明人： Gil G. Mor , Donna Neale , Roberto Romero
IPC分类号： G01N33/48 , C07K1/00
CPC分类号： G01N33/689 , G01N2500/00 , G01N2800/368
摘要： The present invention provides methods and compositions related to biomarker profiles for each trimester of pregnancy. The present invention also provides methods for identifying patients at risk of developing a complication of pregnancy, such as preeclampsia. In further embodiments, the present invention relates to methods for the diagnosis of patients with preeclampsia.
摘要翻译：本发明提供了与妊娠三个月的生物标志物谱相关的方法和组合物。本发明还提供了鉴定患有发生妊娠并发症的风险的患者的方法，例如先兆子痫。在进一步的实施方案中，本发明涉及诊断先兆子痫患者的方法。

6. 发明申请

US20120251630A1 REMISSION THERAPY OF CANCER WITH ISOFLAVONOIDS 审中-公开
标题翻译：癌症与ISOFLAVONOIDS的复发治疗
公开(公告)号：US20120251630A1
公开(公告)日：2012-10-04
申请号：US13434665
申请日：2012-03-29
申请人： Ayesha B. Alvero , Daniel P. Gold , Gil G. Mor
发明人： Ayesha B. Alvero , Daniel P. Gold , Gil G. Mor
IPC分类号： A61K31/353 , A61K31/7068 , C12N5/095 , A61K31/4745 , A61P35/00 , A61K33/24 , A61K31/7048
CPC分类号： A61K31/353 , A61K45/06 , A61K2300/00
摘要： Provided herein is a method of reducing incidences of cancer recurrence. The method involves administering to an individual in cancer remission an isoflavonoid. In specific instances, the treated individual is in remission from epithelial cancer, such as ovarian cancer or breast cancer.
摘要翻译：本文提供了减少癌症复发发生率的方法。该方法涉及给个体在癌症缓解中给予异黄酮。在具体情况下，被治疗的个体从上皮癌如卵巢癌或乳腺癌中缓解。

7. 发明授权

US07985538B2 Drug resistance and methods of reversing 有权
标题翻译：耐药性和逆转方法
公开(公告)号：US07985538B2
公开(公告)日：2011-07-26
申请号：US12224244
申请日：2007-02-23
申请人： Gil G. Mor
发明人： Gil G. Mor
IPC分类号： C12Q1/00 , G01N33/53
CPC分类号： G01N33/57449 , G01N33/57496 , G01N2800/44
摘要： Described herein is a cellular marker, MyD88, useful for assessing an individual's (patient's) sensitivity (or resistance) to chemotherapy, particularly sensitivity (or resistance) to chemotherapeutic drugs, such as plant alkaloids (e.g., a taxane, such as paclitaxel or docetaxel). As described herein, Applicants provide a method by which it is possible to determine whether an individual (cancer cells in an individual) is sensitive to chemotherapy with plant alkaloids (e.g., a taxane, such as paclitaxel or docetaxel). Early identification of chemoresistance in patients with cancer is of utmost importance, particularly since it makes it possible to provide the most appropriate therapy.
摘要翻译：本文描述的是一种细胞标志物MyD88，可用于评估个体（患者）对化学疗法的敏感性（或抗药性），特别是化疗药物如植物生物碱（例如紫杉烷如紫杉醇或多西紫杉醇）的敏感性（或抗性））。如本文所述，申请人提供了一种方法，通过该方法可以确定个体（个体中的癌细胞）是否对植物生物碱（例如紫杉烷如紫杉醇或多西他赛）的化学疗法敏感。早期鉴定癌症患者的化疗耐药性至关重要，特别是因为它可以提供最合适的治疗方法。

8. 发明申请

US20090220427A1 Drug Resistance and Methods of Reversing 有权
标题翻译：耐药性和逆转方法
公开(公告)号：US20090220427A1
公开(公告)日：2009-09-03
申请号：US12224244
申请日：2007-02-23
申请人： Gil G. Mor
发明人： Gil G. Mor
IPC分类号： A61K49/00 , G01N33/574 , A61P35/00
CPC分类号： G01N33/57449 , G01N33/57496 , G01N2800/44
摘要： Described herein is a cellular marker, MyD88, useful for assessing an individual's (patient's) sensitivity (or resistance) to chemotherapy, particularly sensitivity (or resistance) to chemotherapeutic drugs, such as plant alkaloids (e.g., a taxane, such as paclitaxel or docetaxel). As described herein, Applicants provide a method by which it is possible to determine whether an individual (cancer cells in an individual) is sensitive to chemotherapy with plant alkaloids (e.g., a taxane, such as paclitaxel or docetaxel). Early identification of chemoresistance in patients with cancer is of utmost importance, particularly since it makes it possible to provide the most appropriate therapy.
摘要翻译：本文描述的是一种细胞标志物MyD88，可用于评估个体（患者）对化学疗法的敏感性（或抗药性），特别是化疗药物如植物生物碱（例如紫杉烷如紫杉醇或多西紫杉醇）的敏感性（或抗性））。如本文所述，申请人提供了一种方法，通过该方法可以确定个体（个体中的癌细胞）是否对植物生物碱（例如紫杉烷如紫杉醇或多西他赛）的化学疗法敏感。早期鉴定癌症患者的化疗耐药性至关重要，特别是因为它可以提供最合适的治疗方法。

9. 发明授权

US07541182B2 In vitro test to detect risk of preeclampsia 有权
标题翻译：检测先兆子痫风险的体外试验
公开(公告)号：US07541182B2
公开(公告)日：2009-06-02
申请号：US10779360
申请日：2004-02-13
申请人： Gil G. Mor , Donna Neale , Roberto Romero
发明人： Gil G. Mor , Donna Neale , Roberto Romero
IPC分类号： C12N5/08
CPC分类号： G01N33/5091 , G01N2510/00
摘要： The present invention provides methods for identifying patients at risk of developing preeclampsia. In further embodiments, the present invention relates to methods for the diagnosis of patients with preeclampsia.
摘要翻译：本发明提供了鉴定患有先兆子痫风险的患者的方法。在进一步的实施方案中，本发明涉及诊断先兆子痫患者的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式